On November 10, 2026, Lisa Nettis notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) of her resignation from the Board, effective on November 26, 2026. Ms. Nettis’ decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
|
Nephros, Inc. is a commercial-stage company that develops and markets point-of-use water filtration solutions, with a core focus on medical-grade applications. The company operates two primary business segments: medical water filtration and commercial water filtration. Its medical portfolio includes infection control filters, featuring microfilters and ultrafilters that retain bacteria, viruses, and endotoxins, and dialysis water filters designed for hemodialysis treatment. These medical-grade products are FDA 510(k)-cleared as Class II medical devices. The commercial segment offers carbon-based and carbon-free filters that improve taste, reduce scale and biofilm, and remove contaminants such as lead, cysts, and Total PFAS. Nephros serves hospitals, dialysis centers, laboratories, manufacturing facilities, aviation environments, and foodservice and hospitality venues. The company sells through a combination of direct sales and value-added resellers (VARs), including a partner focused on the food service and hospitality sectors. Founded in 1997 with a focus on the end-stage renal disease marketplace, Nephros acquired Biocon 1, LLC and Aether Water Systems, LLC in 2019 to expand its commercial filtration lineup. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Specialty Chemicals | Homepage nephros.com |
| Sector Basic Materials | IR page nephros.com/investors | |
|
Tags
water filtration, medical devices, infection control, dialysis, hollow fiber membranes, pfas removal, point-of-use filtration, healthcare facilities, foodservice, industrial filtration, Biocon 1 LLC, Aether Water Systems LLC
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 30.871M |
| Market cap (USD) | $ 30.871M |
| P/E | 25.82 |
| PEG | — |
| P/BV | 2.46 |
| P/S | 1.43 |
| P/OCF | -33.92 |
| P/FCF | 18.77 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 12.7% |
| ROI | 24.8% |
| ROIC | 23.6% |
| Profit margin | 6.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 3 |
| Quality score | 17.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.789M | 14.162M | 14.238M | 9.975M | 10.404M | 8.561M | 10.334M | 5.687M | 3.809M | 2.32M | 1.944M | 1.748M | 1.74M | 1.807M | 2.214M | 2.938M | 2.661M | 1.473M | 1.196M |
| Net profit | 1.194M | 74K | -1.575M | -7.106M | -3.867M | -4.526M | -3.42M | -3.402M | -809K | -3.032M | -3.088M | -7.371M | -3.698M | -3.262M | -2.36M | -1.933M | -2.026M | -6.337M | -26.356M |
| Free cash flow | 1.645M | -547K | 752K | -3.371M | -1.453M | -7.142M | -2.29M | — | — | -2.157M | -3.828M | — | -3.583M | -1.555M | — | -1.322M | -2.64M | -5.822M | -6.587M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 4.88 | 1.47 | 3.46 | 1.15 | 5.9 | 8.58 | 9.95 | 0.45 | 0.5 | 0.37 | 0.21 | 0.76 | 0.39 | — | — | — | 1.95 | — | — |
| Price performance 12m | 2.32 | -0.58 | 2 | -0.8 | -0.31 | -0.14 | 21.12 | -0.1 | 0.37 | 0.71 | -0.72 | 0.97 | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 388,000 | 836,000 | 1.45M | 1.05M | 1.36M | 1.64M | 1.29M | 1.5M | 1.78M | 2.41M |
| ↳ YoY growth | -2.3% | +115.5% | +73.7% | -28.0% | +30.5% | +20.3% | -21.6% | +16.3% | +19.1% | +35.5% |
| ↳ 5y CAGR | +64.1% | +56.9% | +28.0% | +33.4% | +9.0% | +0.6% | +11.3% | +12.1% | ||
| Lease liabilities (USD) | — | — | 621,000 | 1.15M | 1.13M | 949,000 | 1.02M | 1.84M | 1.41M | 1.06M |
| Cash and deposits (USD) | — | — | — | 4.17M | 8.25M | 6.97M | 3.63M | 4.31M | 3.76M | 5.4M |
| Intangible assets (USD) | 2.25M | 2.25M | 590,000 | 548,000 | 506,000 | 1.54M | 423,000 | 381,000 | 349,000 | 318,000 |
| Right-of-use assets (USD) | — | — | 613,000 | 1.11M | 1.04M | 867,000 | 972,000 | 1.8M | 1.36M | 1M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -2.11M | -77,000 | -3.66M | -2.28M | -6.9M | -1.42M | -3.23M | 827,000 | -492,000 | 1.65M |
| Purchases of property, plant and equipment (USD) | -45,000 | — | — | -14,000 | -239,000 | -36,000 | -137,000 | -75,000 | -55,000 | — |
| Change in receivables (cash effect) (USD) | -17,000 | -416,000 | -484,000 | 392,000 | -333,000 | -278,000 | 357,000 | -221,000 | -285,000 | -633,000 |
| Change in inventories (cash effect) (USD) | 103,000 | -195,000 | -1.08M | -735,000 | -2.76M | 296,000 | 915,000 | 387,000 | -407,000 | -685,000 |
| Change in payables (cash effect) (USD) | -76,000 | 268,000 | -130,000 | 119,000 | -538,000 | 908,000 | -593,000 | 133,000 | -220,000 | 259,000 |
| Interest paid (cash effect) (USD) | -113,000 | -148,000 | -150,000 | -139,000 | -93,000 | -41,000 | -19,000 | -2,000 | -2,000 | -1,000 |
| Income taxes paid (cash effect) (USD) | -11,000 | -7,000 | -4,000 | -5,000 | -22,000 | -79,000 | — | — | — | — |
| Share-based compensation (USD) | 551,000 | 772,000 | 985,000 | 1.33M | 779,000 | 1.26M | 982,000 | 1.05M | 153,000 | 296,000 |
| Operating cash flow before change in receivables (USD) | -2.1M | 339,000 | -3.18M | -2.67M | -6.57M | -1.14M | -3.59M | 1.05M | -207,000 | 2.28M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -2.16M | — | — | -2.29M | -7.14M | -1.45M | -3.37M | 752,000 | -547,000 | — |
| Income detail | ||||||||||
| Research and development expense (USD) | 1.08M | 1M | 1.54M | 3.09M | 2.76M | 2.17M | 1.26M | 873,000 | 906,000 | 1.34M |
| ↳ 5y CAGR | +19.1% | +9.7% | +13.3% | +31.7% | +27.3% | +15.0% | +4.6% | -10.7% | -21.8% | -13.5% |
| Total comprehensive income (USD) | -3.04M | -799,000 | -3.41M | -3.43M | -4.52M | -3.88M | -7.12M | -1.58M | — | — |
| Comprehensive income to owners (USD) | -3.04M | -799,000 | -3.41M | -3.19M | -4.76M | -4.12M | -7.4M | -1.58M | — | — |
| Provision for credit losses (USD) | 35,000 | — | 40,000 | 15,000 | 11,000 | 1,000 | -1,000 | 11,000 | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 8.9% | — | 3.5% | 1.2% | 0.9% | 0.1% | 0.1% | 0.8% | — | — |
| Reported | Mar 20, 2017 | Feb 26, 2018 | May 8, 2019 | May 6, 2020 | Mar 1, 2021 | Aug 15, 2022 | Mar 23, 2023 | Mar 15, 2024 | Mar 24, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR.
Call: 201 343 5202
nephros.com
Nephros Announces Date for 2026 Annual Meeting of Stockholders
2026 Annual Meeting of Stockholders to Be Held Virtually on November 25, 2026
SOUTH ORANGE, NJ – October 13, 2026 – Nephros, Inc. (NASDAQ: [NEPH]) (“Nephros” or the “Company”) today announced that its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) will be held on Wednesday, November 25, 2026, at 11:00 a.m., Eastern Time. The meeting will be held virtually and conducted live via webcast. The time, agenda and instructions for attending the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement. That proxy statement will be sent to stockholders entitled to notice of and to vote at the 2026 Annual Meeting.
The Board of Directors has fixed the close of business on September 30, 2026 as the record date for determining the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting.
The 2026 Annual Meeting will be held more than 30 days after the anniversary of the Company’s 2025 Annual Meeting of Stockholders, which was held on June 16, 2025.
Call: 201 343 5202
nephros.com
Nephros Announces Strong Third Quarter 2026 Financial Results
Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026.
SOUTH ORANGE, NJ, November 5, 2026 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2026.
Financial Highlights
● Net revenue increased 18% to $5.6 million, compared to $4.8 million in the third quarter of 2025
● Net income was $0.5 million, compared to net income of $0.3 million in the third quarter of 2025
● Adjusted EBITDA was $0.6 million, compared to $0.4 million in the third quarter of 2025
“The third quarter of 2026 continued the strong momentum we have built across Nephros,” said Robert Banks, President and Chief Executive Officer of Nephros. “Net revenue increased approximately 18% over the prior-year quarter to $5.6 million, following the record $6.0 million we reported in the second quarter.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Nephros, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.